MDLZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MDLZ looks like a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock is showing a constructive technical setup, analysts are broadly positive and have recently raised price targets after a strong Q1, and options sentiment is mildly bullish. Given the current pre-market price of 63.51, the stock is trading near resistance but still within a healthy uptrend, so I would rate it as a buy now rather than waiting for a perfect pullback.
The technical picture is bullish. MACD histogram is positive and expanding, RSI_6 at 63.784 shows momentum without being overbought, and the moving averages are aligned bullishly with SMA_5 > SMA_20 > SMA_200. Price is near first resistance at 63.771, with support at the pivot 62.09 and stronger support at 60.409. In the near term, the trend favors continuation upward, and the pre-market move above the prior close suggests buyers are still active.
Recent analyst revisions are favorable after Q1 results, with several firms lifting targets to the mid-to-high $60s and $70 on improving earnings estimates. BofA noted that Q1 restored solid footing after volatility, and Barclays described a clean beat across the board. The company also appears to be seeing better execution in U.S. biscuits and benefits from cost deflation and margin recovery. The news flow is mostly unrelated to MDLZ directly, but the company-specific item about SOUR PATCH KIDS launching BESTIES candy is a modest product-marketing positive.
Some analysts remain neutral and note that much of the upside may be reinvested back into the business, which can limit near-term EPS surprise. Macro uncertainty and cocoa cost pressures have been mentioned, and valuation upside may depend on clearer visibility into 2027 earnings growth. There is no meaningful insider or hedge fund accumulation signal, and there is no recent congress trading support.
The latest available quarter is Q1 2026. Financial commentary points to stronger-than-expected Q1 EPS of 67 cents, better organic sales growth, and solid margin performance. Management reaffirmed 2026 guidance, and analysts said the quarter improved the setup for the stock. The overall growth trend looks steady rather than explosive, but the business appears to be stabilizing and improving.
Analyst sentiment is positive overall. BofA, Evercore ISI, JPMorgan, TD Cowen, Barclays, and BTIG are constructive, with multiple Buy/Overweight/Outperform ratings and recent target increases to roughly $67-$71. Piper Sandler and UBS remain Neutral, mainly due to reinvestment needs and limited immediate upside. The Wall Street pros view is favorable: the bull case is supported by improving fundamentals and margin recovery, while the bear case centers on muted near-term upside and reinvestment tradeoffs.
